Clicky

Eledon Pharmaceuticals, Inc.(ELDN) News

Date Title
Sep 4 Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
Jul 29 Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
Jun 3 Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
May 9 Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
May 9 Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
May 7 Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
May 7 Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
Mar 28 Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
Mar 25 Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
Mar 21 Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
Jan 4 Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
Dec 4 Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 29 Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
Nov 9 Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
Nov 8 Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
Nov 2 Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation